Recent studies offer new insights into ALK detection methods and related treatments. Screening for the non-small cell lung cancer (NSCLC) subtype has been at the forefront of NSCLC research, and ...

Circulating Human Papillomavirus DNA as a Biomarker of Response in Patients With Locally Advanced Cervical Cancer Treated With Definitive Chemoradiation Patients age ≥ 18 years with two or more visits ...

Routine testing with both fluorescent in situ hybridization and immunohistochemistry may enhance the detection of ALK-positive non-small cell lung cancer, new research suggests. Accurate determination ...

ABBOTT PARK, Ill., Oct. 24, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it will expand the current CE-IVD product labeling for its Vysis ® ALK Break Apart FISH Probe Kit, allowing the ...

Simultaneous Approval of New Treatment and Companion Diagnostic Represents Significant Advance in Personalized Medicine for Patients with Non-Small-Cell Lung Cancer Abbott Park, Illinois (NYSE: ABT) - ...

DENVER – Sixteen institutions across Europe collaborated together to show for the first time that a semi-quantitative anaplastic lymphoma kinase (ALK) protein expression test, immunohistochemistry ...

LOS ANGELES--(BUSINESS WIRE)--Response Genetics Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced that it has expanded its ...

Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced approval of the VENTANA ALK (D5F3) CDx Assay by the US Food and Drug Administration (FDA) as a companion ...

Within the final analytic cohort (N = 156), 93.9% of the respondents practicing in the private sector (n = 147) reported access to ALK testing, whereas only 43.9% of those practicing in the public ...

Sixteen institutions across Europe collaborated together to show for the first time that a semi-quantitative anaplastic lymphoma kinase (ALK) protein expression test, immunohistochemistry (IHC), is ...